MedPath

An Application Provides Temperature-related Health Risk Warnings and Protective Recommendations on Stroke

Not Applicable
Not yet recruiting
Conditions
Acute Ischemic Stroke
Registration Number
NCT07097428
Lead Sponsor
Xuanwu Hospital, Beijing
Brief Summary

This study applied an application to provide early warnings and advice for stroke patients and explored the impact of this intervention on reducing the risk of stroke recurrence

Detailed Description

This study applied an application that provides individualized environmental temperature-related health risk warnings and recommendations to stroke patients, enabling them to promptly understand their risk levels and take corresponding protective measures. And explore the effect of this actual intervention on reducing the risk of stroke recurrence after one year, as well as changes in other health-related indicators.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
5092
Inclusion Criteria
  • Aged 40 to 80, with no gender restrictions;

    • Acute ischemic stroke inpatients within 2 weeks of onset, where the onset time is the time when stroke symptoms appear or the last known normal time of the patient (when it is an onset during sleep or the symptom onset time cannot be accurately obtained due to aphasia, impaired consciousness, etc.);

      • Confirmed diagnosis of ischemic stroke by CT or MRI of the brain within 2 weeks after symptom onset;

        • Local residents (residing for ≥6 months); ⑤ Patients who voluntarily participate in the study, have high compliance, and can sign the informed consent form;

          • Patients who own a smartphone or other smart devices.
Exclusion Criteria
  • Patients diagnosed with other cerebrovascular diseases (hemorrhagic stroke, transient ischemic attack, cerebral venous sinus thrombosis, etc.) or non-cerebrovascular diseases;

    • Known pregnant or lactating women, or those who tested positive on a pregnancy test before cluster randomization;

      • Patients with other conditions that may affect participation in the trial (e.g., refractory hypertension, severe aphasia, etc.);

        • Patients undergoing psychiatric/psychological treatment that may contaminate the results; ⑤ Patients with a life expectancy of less than one year (e.g., coexisting malignant tumors, severe cardiopulmonary diseases, etc.); ⑥ Patients already participating in other interventional clinical studies that may influence the outcome assessment; ⑦ Patients for whom the investigator deems unsuitable for participation in this study or who may pose significant risks to the patients (e.g., cognitive impairment preventing understanding and/or compliance with the study procedures and/or follow-up).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
1-year recurrence rate of strokeIntervention at the 1-year
Secondary Outcome Measures
NameTimeMethod
Blood pressureBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

Systolic and diastolic blood pressure will be measured using a standard automated sphygmomanometer

Electrocardiogram (ECG) parametersBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

Electrocardiogram (ECG) will be performed to assess cardiac electrical activity. Specific parameters will be analyzed, such as heart rate (beats per minute (bpm)), QT interval (milliseconds (ms)), PR interval (milliseconds (ms)), QRS duration (milliseconds (ms))

Environmental temperature health risk perception assessment questionnaireBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

It is used to assess patients' understanding and concern about health hazards related to temperature. The lower the score, the less they understand or are concerned about it

System usability scale scoreIntervention at 3-month, 6-month, 9-month and 1-year

It is used to understand the subjects' satisfaction and usability evaluation of the intelligent program. The higher the score, the better the evaluation

Lipid Profile (Total Cholesterol, LDL-C, HDL-C, and Triglycerides)Baseline; Intervention at 3-month, 6-month, 9-month and 1-year

Plasma lipid levels will be measured using standard laboratory assays, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG).

Fasting blood glucoseBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

Fasting plasma glucose levels will be measured to assess glycemic control.

Coagulation parameters (Prothrombin Time, aPTT, INR, Fibrinogen, Platelet Count and D-dimer)Baseline; Intervention at 3-month, 6-month, 9-month and 1-year

Coagulation status will be assessed using standard coagulation tests, including prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR), fibrinogen level, platelet count and D-dimer.

C-reactive proteinBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

Blood samples will be analyzed using immunoassay techniques on automated analyzers

Modified rankin scale scoreBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

The functional recovery of patients was evaluated using the modified rankin scale. The higher the score, the more serious it is

NIH stroke scale scoreBaseline

The neurological deficits on the NIHSS scale indicate that the higher the score, the more severe the stroke

Social support rate scale scoreBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

It is used to understand the support that patients receive in society, and the higher the score, the more support they receive

Depression anxiety stress scales - 21 scoreBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

It is used to understand the patient's emotional state. The higher the score, the worse the mood

European five-dimensional five-level health scale scoreBaseline; Intervention at 3-month, 6-month, 9-month and 1-year

It is used to assess an individual's health-related quality of life, consisting of two parts: a questionnaire and a visual analog scale (VAS). The questionnaire includes five dimensions, where higher scores indicate worse health status. The visual analog scale asks respondents to rate their overall health on a 0-100 scale, with higher scores reflecting better self-rated health status.

Minimum mental state examinationBaseline; Intervention at 6-month and 1-year

It is used to screen patients' cognitive conditions. The lower the score, the worse the cognition

3-month, 6-month, 9-month recurrence rate of strokeIntervention at 3-month, 6-month, 9-month

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.